Compare Ascendis Pharma A/S (ASND) vs Schlumberger NV (SLB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Schlumberger NV — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Schlumberger NV trades at $48.18 (market cap $71.40B). The key difference: Schlumberger NV is far larger — about 4× Ascendis Pharma A/S's market cap, and Schlumberger NV pays a 2.47% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | SLB | |
|---|---|---|
Market Cap | $17.74B | $71.40B |
Sector | Health | Energy |
52-Week High | $277.18 | $58.01 |
52-Week Low | $163.32 | $31.72 |
Enterprise Value | $18.11B | $79.62B |
Dividend Yield | — | 2.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
SLB trades at $47.76, up 1.1% with a bullish technical signal despite recent volatility. The company reported Q1 2026 EPS of $0.52, beating expectations, and maintains strong cash flow from operations at $6.49B. Recent news highlights a seven-year Kuwait contract expansion and digital marketplace launch, supporting growth prospects amid oil price fluctuations.
Outlook: Analyst consensus is bullish with an $62.14 price target (30% upside). Risks include oil price sensitivity and Middle East exposure, but digital transformation and contract wins provide stability. Valuation metrics (P/E 21.04, P/S 1.95) appear reasonable relative to historical performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →
